Randox is committed to developing state-of-the-art technology including chemistry, immunoassay, molecular and POC platforms, in addition to complete quality control solutions and high-quality first- and third-party reagents.
Developing the gold standard in testing, Randox patented Biochip Technology presents unique testing capabilities by enabling a multiplex testing method. This has found application in hospitals, clinical research and molecular laboratories, food testing, forensic toxicology, veterinary laboratories and POCT. Randox adapts quickly to meet market demands and currently offers a diverse range of testing solutions for COVID-19.
Utilising its Biochip Technology capable of conducting multiple tests simultaneously, the Randox Biochip has two tests for COVID-19, one specific and one confirmatory, both run on the all-in-one
molecular solution, Vivalytic, a universal, fully automated, cartridge-based platform.